SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-30. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
=== Legal status === In May 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ablymico, indicated for weight management as an adjunct to a reduced-calorie diet and increased physical activity. The applicant for this medicinal product is STADA Arzneimittel AG. Ablymico is a hybrid medicine of liraglutide (Saxenda), which has been authorized in the European Union since March 2015. Ablymico contains the same active substance as Saxenda, but it is chemically synthesized, whereas the active substance in the reference products is of biological origin. Ablymico was authorized for medical use in the European Union in July 2026. In May 2026, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Liraglutide Stada, intended for the treatment of insufficiently controlled type 2 diabetes. The applicant for this medicinal product is STADA Arzneimittel AG. Liraglutide Stada is a hybrid medicine of liraglutide (Victoza), which has been authorized in the European Union since June 2009. Liraglutide Stada contains the same active substance as Victoza, but it is chemically synthesized, whereas the active substance in the reference products is of biological origin.
Treatment should take into account the cause and severity of the condition. If the iron-deficiency anemia is a result of blood loss or another underlying cause, treatment is geared toward addressing the underlying cause. Most cases of iron deficiency anemia are treated with oral iron supplements. In severe acute cases, treatment measures are taken for immediate management in the interim, such as blood transfusions or intravenous iron. For less severe cases, treatment of iron-deficiency anemia includes dietary changes to incorporate iron-rich foods into regular oral intake and oral iron supplementation. Foods rich in ascorbic acid (vitamin C) can also be beneficial, since ascorbic acid enhances iron absorption. Oral iron supplements are available in multiple forms. Some are in the form of pills, and some are drops for children. Most forms of oral iron replacement therapy are absorbed well by the small intestine; however, there are certain preparations of iron supplements that are designed for longer release in the small intestine than other preparations. Oral iron supplements are best taken up by the body on an empty stomach because food can decrease the amount of iron absorbed from the small intestine. The dosing of oral iron replacement therapy is as much as 100–200 mg per day in adults and 3–6 mg per kilogram in children. This is generally spread out as 3–4 pills taken throughout the day. The various forms of treatment are not without possible adverse side effects.
On January 31, 1958, nearly four months after the launch of Sputnik 1, aerospace and space engineer, Dr. Wernher von Braun and the United States successfully launched its first satellite on a four-stage Juno I rocket derived from the US Army's Redstone missile, at Cape Canaveral. The satellite Explorer 1 was 30.66 pounds (13.91 kg) in mass. The payload of Explorer 1 weighed 18.35 pounds (8.32 kg). It carried a micrometeorite gauge and a Geiger–Müller tube. It passed in and out of the Earth-encompassing radiation belt with its 194-by-1,368-nautical-mile (360 by 2,534 km) orbit, therefore saturating the tube's capacity and proving what Dr. James Van Allen, a space scientist at the University of Iowa, had theorized. The belt, named the Van Allen radiation belt, is a doughnut-shaped zone of high-level radiation intensity around the Earth above the magnetic equator. Van Allen was also the man who designed and built the satellite instrumentation of Explorer 1. The satellite measured three phenomena: cosmic ray and radiation levels, the temperature in the spacecraft, and the frequency of collisions with micrometeorites. The satellite had no memory for data storage, therefore it had to transmit continuously. The next successful mission was Explorer 3, launched later that month (March 26, 1958), which carried similar scientific instruments and successfully recorded cosmic ray data.
Sources: en.wikipedia.org
VanA - enterococcal resistance to vancomycin and teicoplanin; inducible on exposure to these agents VanB - lower-level enterococcal resistance; inducible by vancomycin, but strains may remain susceptible to teicoplanin VanC - least clinically important; enterococci resistant only to vancomycin; constitutive resistance A variant of vancomycin has been tested that binds to the resistant D-lactic acid variation in vancomycin-resistant bacterial cell walls and also binds well to the original target (vancomycin-susceptible bacteria).
Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions.Chaudhary AK, Singh M, Bharti AC, Singh M, Shukla S, Singh AK, Mehrotra R. BMC Cancer. 2010 Jul 14;10:369.
== Cause == There are two genetic traits linked to feline cutaneous asthenia. One comes from a dominant allele, while the other comes from a recessive. Both result in similar pathology. Cats with the autosomal dominant form of feline cutaneous asthenia package type I collagen poorly. Collagen is a major component in skin tissue and in tendons. While scientists originally suspected that the problem lay in the production of the type I collagen molecule, it is now known that type V collagen is the molecule which is incorrectly produced. Although scientists do not know exactly how, many suspect that type V collagen assists in packaging type I collagen. Collagen fibrils are often abnormally sized and have unusually large amounts of space between them. The dermis is thinned because of this. In heterozygous cats, normal and abnormal fibrils often exist inside of the same collagen fiber. Homozygous cats are not likely to survive for very long. The autosomal recessive form of feline cutaneous asthenia results in a deficiency of procollagen peptidase or a structural abnormality at its cleavage site. Procollagen peptidase is an enzyme necessary for the post-translational modification of procollagen into collagen. Because of the abnormalities in the formation of collagen fibrils, affected cats produce twisted collagen ribbons, rather than the normal collagen cylinders one would expect to find.
Red Acid fuchsin, xylidine ponceau, chromotrope 2R, Biebrich scarlet, ponceau 6R, phloxine Blue and green Light green SF yellowish, Fast Green FCF, methyl blue, water blue Yellow Picric acid, orange G, Martius yellow, tartrazine, milling yellow
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.